Cape Investment Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cape Investment Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.65K	Buy	+11	New	+$2.41K	﹤0.01%	1179
2026 Q1	–	Sell	-6	Closed	-$1.02K	–	716
2025 Q4	$1.02K	Buy	+6	New	+$920	﹤0.01%	1188
2025 Q3	–	Sell	-2	Closed	-$212	–	1016
2025 Q2	$212	Hold	2	–	–	﹤0.01%	1115
2025 Q1	$248	Hold	2	–	–	﹤0.01%	1044
2024 Q4	$246	Hold	2	–	–	﹤0.01%	1042
2024 Q3	$223	Hold	2	–	–	﹤0.01%	921
2024 Q2	$213	Hold	2	–	–	﹤0.01%	894
2024 Q1	$241	Sell	2 -292	-99%	-$35.8K	﹤0.01%	900
2023 Q4	$36.2K	Buy	294 +292	+14,600%	+$36.4K	0.02%	411
2023 Q3	$259	Hold	2	–	–	﹤0.01%	892
2023 Q2	$248	Hold	2	–	–	﹤0.01%	877
2023 Q1	$293	Buy	+2	New	+$296	﹤0.01%	924

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Cape Investment Advisory's JAZZ Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 11 shares worth $2.65K. The stake represents ﹤0.01% of the portfolio and ranks #1179 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in JAZZ as recently as Q4 2025.

Cape Investment Advisory first reported a position in JAZZ in Q1 2023 and has held it in 12 quarters since. The position peaked at $36.2K in Q4 2023. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Cape Investment Advisory held 11 shares of Jazz Pharmaceuticals worth $2.65K as of Q2 2026.
Jazz Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1179 holding.
Cape Investment Advisory first reported a position in Jazz Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Cape Investment Advisory's Jazz Pharmaceuticals position peaked at $36.2K in Q4 2023.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.